Abstract: Compositions containing as active ingredients a lipid-soluble benzoquinone, e.g. Coenzyme Q10 and at least one omega-3 polyunsaturated fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and linolenic acid (LNA), for the prevention and/or treatment of mitochondriopathies.
Abstract: This invention relates to a method of producing analgesia in a mammal experiencing pain by systemically administering an effective amount of a composition comprising essentially of a sodium channel blocking compound, in a suitable pharmaceutical vehicle, to alleviate the pain.
Abstract: A composition formulated for dose-wise delivery to a breathing passageway of a human, the composition comprising a carrier solution containing (+)naloxone and a pharmacologically effective amount of at least one adrenergic agonist, the (+)naloxone and agonist forming a mixture in the carrier. The at least one adrenergic agonist is selected from the group consisting of epinephrine, isoproterenol, albuterol, aminophylline, beclomethasone, dyphylline, flunisolide, isoetharine, metaproterenol, oxtriphylline, terbutaline, theophylline, pseudoephedrine, phenylephrine, ephedrine and norepinephrine. That composition is delivered by an atomizer means such as a liquid sprayer or inhaler to treat nasal congestion and asthmatic attacks. Further provided by the invention is a cardiovascular and respiratory stimulating composition for administration to a patient in doses, the composition comprising a pharmacologically effective concentration of (+)naloxone in a carrier solution.
Type:
Grant
Filed:
April 27, 2000
Date of Patent:
September 4, 2001
Assignee:
The University of North Texas Health Science Center at Fort
Worth
Abstract: A natural method for promoting fat, and weight loss while decreasing food cravings comprising administrating to an individual in need thereof L-carnitine, chromium, coenzyme Q10, creatine, lipoic acid, niacin, pyruvate, riboflavin, and thiamine. Pyruvate is a major promoter of the oxidation of dietary fuels like carbohydrates and fatty acids in the citric acid cycle. L-carnitine allow the transport of fatty acids into the mitochondria were they can be degraded in the citric acid cycle. Lipoic acid is a major intracellular antioxidant, and component of key enzymes in the citric acid cycle. Niacin, riboflavin, and thiamine are key components of enzymes that lead to the breakdown of dietary fuel molecules such as fatty acids, amino acids, and carbohydrates that enter the citric acid cycle. The breakdown of these dietary fuels leads to the production of high energy hydrogen atoms. Coenzyme Q10 accepts these hydrogen atoms and utilizes them for cellular energy production.
Abstract: TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are characterized by a reduced vessel lumen diameter. In a preferred embodiment of the invention, TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation and/or migration of vascular smooth muscle cells over time.
Type:
Grant
Filed:
November 6, 1997
Date of Patent:
December 26, 2000
Assignee:
NeoRx Corporation
Inventors:
David J. Grainger, James C. Metcalfe, Peter L. Weissberg
Abstract: A method of administering an amino acid protocol intravenously for the treatment of a patient suffering from an autoimmune disease is provided.
Abstract: A method for prevention of atherosclerosis or for treatment of hyperlipidaemia or atherosclerosis comprises administering a compound or a mixture of compounds according to formula (I) ##STR1## as defined herein.
Abstract: A vitamin E source composition for administration to animals, which comprises a tocopheryl phosphate, a salt thereof or a composition containing a tocopheryl phosphate or a salt thereof. Also, disclosed is a method of supplying vitamin E to animals which comprises administering to animals the above vitamin E source composition. The tocopheryl phosphoric acid and a salt thereof can be formed into a composition and also can contain an antioxidant or the like.
Abstract: A method for preparing streptogramins of the formula (I): ##STR1## wherein R.sub.1 is methyl or ethyl, R.sub.2 is H and X and Y together form an oxo radical, or R.sub.1 is ethyl, R.sub.2 and X are H and Y is H or OH, or else R.sub.1 is ethyl, R.sub.2 is OH and X and Y together form an oxo radical, by demethylation of a synergistin derivative of the formula (II): ##STR2## wherein R.sub.1, R.sub.2, X and Y are as defined above, by means of a treatment with a periodate in an acetic medium, followed by a treatment in an aqueous medium.
Type:
Grant
Filed:
October 16, 1997
Date of Patent:
August 4, 1998
Assignee:
Rhone-Poulenc Rorer S.A.
Inventors:
Jean-Claude Barriere, Luc Grondard, Patrick Lefevre, Stephane Mutti